Spectrum and Incidence Trends of AIDS- and Non-AIDS-Defining Cancers between 2010 and 2015 in the French Dat'AIDS Cohort

• Published in: Cancer epidemiology, biomarkers & prevention Vol. 30; no. 3; pp. 554 - 563
• Main Authors: Poizot-Martin, Isabelle, Lions, Caroline, Allavena, Clotilde, Huleux, Thomas, Bani-Sadr, Firouze, Cheret, Antoine, Rey, David, Duvivier, Claudine, Jacomet, Christine, Ferry, Tristan, Cabie, André, Fresard, Anne, Pugliese, Pascal, Delobel, Pierre, Lamaury, Isabelle, Chirouze, Catherine, Zaegel-Faucher, Olivia, Brégigeon, Sylvie, Rojas Rojas, Teresa, Obry-Roguet, Véronique, Makinson, Alain
• Format: Journal Article
• Language: English
• Published: United States American Association for Cancer Research 01.03.2021
• Subjects: Acquired Immunodeficiency Syndrome - complications; Acquired Immunodeficiency Syndrome - epidemiology; Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Female; History, 21st Century; Human health and pathology; Humans; Incidence; Life Sciences; Male; Microbiology and Parasitology; Middle Aged; Neoplasms - epidemiology; Young Adult
• ISSN: 1055-9965; 1538-7755
• DOI: 10.1158/1055-9965.EPI-20-1045

Cancer risk is higher in people living with HIV (PLWH) compared with the general population, and cancers related to age are expected to be most prevalent. We determined the spectrum and incidence rates of AIDS-defining cancers (ADC) and non-AIDS-defining cancers (NADC) and of lung, Hodgkin lymphoma (HL), head and neck (HNC), colon-rectum, anal, liver, breast, prostate, and urinary bladder cancers between January 2010 and December 2015 in the French Dat'AIDS cohort. Incidence rates were calculated by year and compared using the test for linear trend. Standardized incidence ratios [SIR (95% confidence interval)] were calculated relative to the French general population. Among 44,642 patients, corresponding to 180,216.4 person-years (PY), 1,440 cancer cases occurred in 1,314 patients. ADC incidence was 191.4 (172.3-212.7)/10 PY and declined over time overall and in men, whereas NADC incidence was higher [548.8 (515.6-584.1)/10 PY] and did not change. In men, non-Hodgkin lymphoma was the most common cancer, but prostate cancer had the highest incidence among NADCs. Breast cancer was the most common cancer in women. SIRs were higher for cervical cancer [1.93 (1.18-3.14)], HNC in women [2.4 (1.4-4.2)], liver [overall: 3.8 (3.1-4.6); men: 3.2 (2.5-4.0); women: 12.9 (8.3-20.0)], and HL [overall: 13.8 (11.1-17.1); men: 16.2 (12.9-20.4); women: 6.2 (3.22-11.9)] but lower for lung [overall: 0.7 (0.6-0.9); men: 0.7 (0.5-0.8)], prostate [0.6 (0.5-0.7)], and breast cancers [0.6 (0.4-0.7)]. Spectrum of NADCs has changed, with prostate and breast cancers becoming the most common despite their lower SIR. These results confirm the need to maintain regular epidemiologic cancer monitoring in order to update screening guidelines.